The opinion supports 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks; a European Commission decision is expected in the coming months.
|Videos|May 10, 2011
Facilitating Intraperitoneal Chemotherapy Completion
Author(s)Fiona McCaughan, RN, MS
Fiona McCaughan on Nurses Facilitating Intraperitoneal Chemotherapy Completion
Advertisement
Fiona McCaughan, RN, MS, OCN® of Hematology Oncology at Winchester Hospital on Nurses Facilitating Intraperitoneal Chemotherapy Completion
Advertisement
Related to this article
With multiple ADCs now available for use in gynecologic cancers, treatment decision-making incorporates biomarker nuances and raises sequencing questions.
Invikafusp alfa now holds fast track status across TMB-H solid tumors that progressed after prior therapy, including checkpoint inhibition.
Advertisement
Advertisement
Trending on OncLive
1
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
2
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
3
Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
4
Dr Warren on the Goal of the 4WARD Trial Evaluating Mavorixafor in Chronic Neutropenia
5